PL2478907T3 - Kompozycje do leczenia nowotworu - Google Patents

Kompozycje do leczenia nowotworu

Info

Publication number
PL2478907T3
PL2478907T3 PL12160586T PL12160586T PL2478907T3 PL 2478907 T3 PL2478907 T3 PL 2478907T3 PL 12160586 T PL12160586 T PL 12160586T PL 12160586 T PL12160586 T PL 12160586T PL 2478907 T3 PL2478907 T3 PL 2478907T3
Authority
PL
Poland
Prior art keywords
compositions
treating cancer
cancer
treating
Prior art date
Application number
PL12160586T
Other languages
English (en)
Polish (pl)
Inventor
Alan H. Auerbach
Arie S. Belldegrun
Original Assignee
Janssen Oncology, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38916904&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2478907(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Oncology, Inc. filed Critical Janssen Oncology, Inc.
Publication of PL2478907T3 publication Critical patent/PL2478907T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PL12160586T 2006-08-25 2007-08-23 Kompozycje do leczenia nowotworu PL2478907T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US92150606P 2006-08-25 2006-08-25
EP07837326.3A EP2061561B1 (en) 2006-08-25 2007-08-23 Compositions for treating cancer
EP12160586.9A EP2478907B1 (en) 2006-08-25 2007-08-23 Compositions for treating cancer
PCT/US2007/018769 WO2008024484A1 (en) 2006-08-25 2007-08-23 Methods and compositions for treating cancer

Publications (1)

Publication Number Publication Date
PL2478907T3 true PL2478907T3 (pl) 2021-10-25

Family

ID=38916904

Family Applications (2)

Application Number Title Priority Date Filing Date
PL12160586T PL2478907T3 (pl) 2006-08-25 2007-08-23 Kompozycje do leczenia nowotworu
PL07837326T PL2061561T3 (pl) 2006-08-25 2007-08-23 Kompozycje do leczenia raka

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL07837326T PL2061561T3 (pl) 2006-08-25 2007-08-23 Kompozycje do leczenia raka

Country Status (20)

Country Link
EP (3) EP2061561B1 (enExample)
JP (10) JP2010501575A (enExample)
KR (4) KR20200125776A (enExample)
CN (2) CN101528308A (enExample)
AU (6) AU2007287098C1 (enExample)
CA (1) CA2661422C (enExample)
CY (2) CY1115477T1 (enExample)
DK (2) DK2061561T3 (enExample)
ES (2) ES2869343T3 (enExample)
HR (2) HRP20130961T1 (enExample)
HU (1) HUE054495T2 (enExample)
IL (3) IL197211A0 (enExample)
LT (1) LT2478907T (enExample)
NO (2) NO20091190L (enExample)
NZ (1) NZ597830A (enExample)
PL (2) PL2478907T3 (enExample)
PT (2) PT2478907T (enExample)
RS (2) RS62034B1 (enExample)
SI (2) SI2478907T1 (enExample)
WO (1) WO2008024484A1 (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200125776A (ko) * 2006-08-25 2020-11-04 코우가 바이오테크놀로지, 인크. 암을 치료하기 위한 방법 및 조성물
US20080051380A1 (en) 2006-08-25 2008-02-28 Auerbach Alan H Methods and compositions for treating cancer
US20090124587A1 (en) * 2007-07-12 2009-05-14 Auerbach Alan H METHODS FOR TREATING CANCER USING 17alpha-HYDROXYLASE/C17,20-LYASE INHIBITORS
WO2009057795A2 (en) * 2007-10-29 2009-05-07 Takeda Pharmaceutical Company Limited Pyrrolo [1,2-c] imidazole derivatives for use im the prophylaxis or treatment of cancer which is refractory to known cancer therapies
CN102558274B (zh) * 2010-12-08 2014-10-15 深圳万乐药业有限公司 一种适合工业化生产醋酸阿比特龙的合成方法
CN102558275A (zh) * 2010-12-20 2012-07-11 天津药物研究院 α型多晶型醋酸阿比特龙结晶、其制备方法、用途和药物组合物
MX356704B (es) 2011-01-11 2018-06-11 Novartis Ag Combinación.
JP6239497B2 (ja) 2011-04-01 2017-11-29 ジェネンテック， インコーポレイテッド Ａｋｔ阻害剤化合物及びアビラテロンの組み合わせ、及び使用方法
US20120295932A1 (en) * 2011-05-17 2012-11-22 Western Connecticut Health Network, Inc. Method for the treatment of cancer
CN103070828B (zh) * 2011-10-26 2016-01-27 山东新时代药业有限公司 一种含醋酸阿比特龙的固体分散体、片剂及其制备方法
CN102336801B (zh) * 2011-10-31 2013-05-15 南京卡文迪许生物工程技术有限公司 醋酸阿比特龙多晶型物和药用组合物
GB201207886D0 (en) * 2012-05-04 2012-06-20 Jagotec Ag Improvements in or relating to organic compounds
CA2872541A1 (en) * 2012-06-06 2013-12-12 Novartis Ag Combination of a 17 -alpha -hydroxylase (c17, 20 - lyase) inhibitor and a specific pi-3k inhibitor for treating a tumor disease
UA117663C2 (uk) 2012-09-26 2018-09-10 Арагон Фармасьютікалз, Інк. Антиандроген для лікування неметастатичного кастраційно-резистентного раку передміхурової залози
CN103800296A (zh) * 2012-11-13 2014-05-21 重庆医药工业研究院有限责任公司 一种稳定的阿比特龙口服固体药物组合物及其制备方法
JOP20200097A1 (ar) * 2013-01-15 2017-06-16 Aragon Pharmaceuticals Inc معدل مستقبل أندروجين واستخداماته
MX2015013247A (es) * 2013-03-15 2016-11-25 Iceutica Inc Formulacion de acetato de abiraterona.
US20150246060A1 (en) 2013-03-15 2015-09-03 Iceutica Inc. Abiraterone Acetate Formulation and Methods of Use
MX2015014046A (es) * 2013-04-04 2016-05-16 Exelixis Inc Combinaciones de farmacos para tratar cancer.
US20150157646A1 (en) 2013-09-27 2015-06-11 Iceutica Inc. Abiraterone Steroid Formulation
EP4265300B1 (en) * 2013-10-01 2025-12-10 Novartis AG Composition comprising a 17 a-hydroxylase/c17,20 lyase (cyp17a1) inhibitor and an akt inhibitor
BR112016006970A2 (pt) * 2013-10-01 2017-08-01 Novartis Ag enzalutamida em combinação com afuresertib para o tratamento de câncer
CN104546745A (zh) * 2013-10-14 2015-04-29 深圳海王药业有限公司 醋酸阿比特龙的片剂组合物及其制备工艺
EP3280448B1 (en) * 2015-04-10 2020-12-30 Capsugel Belgium NV Abiraterone acetate lipid formulations
SI3490560T1 (sl) 2016-07-29 2025-04-30 Janssen Pharmaceutica, N.V. Niraparib za uporabo pri metodi zdravljenja raka prostate
JOP20190244A1 (ar) * 2017-04-13 2019-10-13 Janssen Pharmaceutica Nv تركيبة علاجية لسرطان البروستاتا
BR112020007439A2 (pt) 2017-10-16 2020-10-27 Aragon Pharmaceuticals, Inc. antiandrogênios para o tratamento de câncer de próstata resistente à castração não metastática
CN109718198A (zh) * 2017-10-30 2019-05-07 浙江京新药业股份有限公司 一种治疗前列腺癌的注射剂及其制备方法
KR102879575B1 (ko) * 2019-03-06 2025-11-03 프로펠라 쎄라퓨틱스, 인크. 아비라테론 프로드러그
WO2021031991A1 (zh) * 2019-08-16 2021-02-25 中国科学院分子细胞科学卓越创新中心 治疗激素依赖性疾病及减少激素依赖性疾病患者药物耐受的组合物和方法
IL297338A (en) * 2020-04-16 2022-12-01 Tavanta Therapeutics Hungary Incorporated Methods and compositions for treating prostate cancer
CN114560903B (zh) * 2022-03-09 2023-08-01 绍兴市上虞区武汉理工大学高等研究院 一种阿比特龙衍生物的制备方法及其细胞毒性评价
LU506495B1 (en) 2024-03-01 2025-09-01 Alfasan Nederland B V 17alpha-HYDROXYLASE/17,20-LYASE (CYP17A1) INHIBITORS FOR THE TREATMENT OF SPONTANEOUS HYPERADRENOCORTICISM IN DOGS

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2265624B (en) 1992-03-31 1995-04-19 British Tech Group 17-substituted steroids useful in cancer treatment
US5604213A (en) 1992-03-31 1997-02-18 British Technology Group Limited 17-substituted steroids useful in cancer treatment
WO2001064251A2 (en) * 2000-03-02 2001-09-07 University Of Pittsburgh Of The Commonwealth System Of Higher Education Combination chemotherapy
AU2002219472A1 (en) * 2001-01-02 2002-07-16 Elisabeth Shanahan-Prendergast Treatment for inhibiting neoplastic lesions using incensole and/or furanogermacrens
DE60318092T2 (de) * 2002-10-23 2008-11-27 Pantarhei Bioscience B.V. Pharmazeutische zusammensetzung enthaltend estetrolderivate und anwendung in der krebsbehandlung
US20050054620A1 (en) * 2003-01-13 2005-03-10 Koeffler H. Phillip Paricalcitol as a chemotherapeutic agent
US20060030608A1 (en) * 2004-08-04 2006-02-09 Boehringer Ingelheim Pharmaceuticals, Inc. Anti aromatase compounds pharmaceutical compositions and uses thereof
GB0418900D0 (en) * 2004-08-24 2004-09-29 Btg Int Ltd Novel salt forms
KR20200125776A (ko) * 2006-08-25 2020-11-04 코우가 바이오테크놀로지, 인크. 암을 치료하기 위한 방법 및 조성물

Also Published As

Publication number Publication date
EP2478907B1 (en) 2021-04-14
CA2661422A1 (en) 2008-02-28
NZ597830A (en) 2013-02-22
JP2018065859A (ja) 2018-04-26
JP2020114851A (ja) 2020-07-30
HUE054495T2 (hu) 2021-09-28
IL197211A0 (en) 2009-12-24
PL2061561T3 (pl) 2013-12-31
JP2021038252A (ja) 2021-03-11
NO20200775A1 (no) 2009-03-20
DK2061561T3 (da) 2013-10-07
EP3804730A1 (en) 2021-04-14
IL227746A0 (en) 2013-09-30
SI2478907T1 (sl) 2021-08-31
AU2007287098C1 (en) 2018-03-15
JP6053279B2 (ja) 2016-12-27
JP2012082215A (ja) 2012-04-26
JP2019059750A (ja) 2019-04-18
JP2010501575A (ja) 2010-01-21
HRP20130961T1 (hr) 2013-11-22
CY1115477T1 (el) 2017-01-04
KR20150108946A (ko) 2015-09-30
KR20090059126A (ko) 2009-06-10
NO20091190L (no) 2009-03-20
JP2015110577A (ja) 2015-06-18
CY1124221T1 (el) 2022-05-27
CN101528308A (zh) 2009-09-09
RS62034B1 (sr) 2021-07-30
AU2021201649A1 (en) 2021-04-08
EP2061561B1 (en) 2013-07-10
LT2478907T (lt) 2021-06-25
HK1131577A1 (en) 2010-01-29
AU2015221447A1 (en) 2015-09-17
RS52956B (sr) 2014-02-28
JP2017052791A (ja) 2017-03-16
AU2015221447B2 (en) 2016-12-15
WO2008024484A1 (en) 2008-02-28
PT2478907T (pt) 2021-05-26
ES2869343T3 (es) 2021-10-25
DK2478907T3 (da) 2021-05-25
PT2061561E (pt) 2013-10-09
HRP20210670T1 (hr) 2021-06-11
AU2015221447B9 (en) 2017-07-20
JP6740497B2 (ja) 2020-08-12
EP2478907A3 (en) 2012-08-01
JP2022185091A (ja) 2022-12-13
CA2661422C (en) 2017-06-27
AU2018271331A1 (en) 2018-12-20
EP2061561A1 (en) 2009-05-27
CN104306977A (zh) 2015-01-28
AU2017201764A1 (en) 2017-04-06
ES2428634T3 (es) 2013-11-08
AU2007287098B2 (en) 2013-08-15
EP2478907A2 (en) 2012-07-25
SI2061561T1 (sl) 2013-11-29
JP2024164147A (ja) 2024-11-26
KR20180003636A (ko) 2018-01-09
IL257681A (en) 2018-04-30
AU2007287098A1 (en) 2008-02-28
AU2022206696A1 (en) 2022-08-11
JP6445123B2 (ja) 2018-12-26
KR20200125776A (ko) 2020-11-04

Similar Documents

Publication Publication Date Title
PL2478907T3 (pl) Kompozycje do leczenia nowotworu
EP2152722A4 (en) COMPOSITIONS COMPRISING MIR34 THERAPEUTIC AGENTS FOR TREATING CANCER
PL3067054T3 (pl) Nowe kompozycje i sposoby leczenia nowotworów
IL190882A0 (en) Compositions for cancer therapy
IL197721A0 (en) Compositions and methods for diagnosing and treating cancer
PL2032166T3 (pl) Kompozycje i sposoby diagnozowania i leczenia nowotworów
PL3009148T3 (pl) Kompozycje oraz sposoby leczenia i diagnozowania nowotworu
IL197914A (en) Antibodies to ereg for cancer treatment
PL2155188T3 (pl) Sposoby i kompozycje do leczenia nawrotowego raka
GB0719181D0 (en) Stain treating composition
ZA201003123B (en) Thiazol derivavtives for treating cancer
IL213398A0 (en) Compounds for treating cancer
SI2205720T1 (sl) Sestavki za zdravljenje multiple skleroze
IL238394B (en) Preparations containing a combination of factors for the treatment of cancer
HRP20130642T1 (en) Methods and compositions for treating cancers
EP2144888A4 (en) METHODS OF TREATING CANCER
EP1979487A4 (en) COBALAMINE COMPOSITIONS FOR THE TREATMENT OF CANCER
EP2174956A4 (en) COMPOSITIONS FOR ANTIFIBRINOLYSIS THERAPY
GB0707556D0 (en) Treatment for cancer
GB0710871D0 (en) Cancer treatment
GB0619271D0 (en) Treating cancer
GB0722030D0 (en) Compositions for treating tumours
PT3067054T (pt) Novas composições e métodos para o tratamento de cancro
SI3067054T1 (sl) Novi sestavki in postopki za zdravljenje raka
GB0604741D0 (en) Cancer Treatment